Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1738-1741

  Beer, Tomasz M ^a   Garzotto, Mark ^a   Eilers, Kristi M ^a   Lemmon, Dianne ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Gonadorelin; Hormone antagonists; Prostatic neoplasms

Indexed keywords

ABARELIX; ANDROGEN; FOLLITROPIN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; ANOREXIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FOLLITROPIN BLOOD LEVEL; GYNECOMASTIA; HORMONE DEPENDENCE; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERCHLOREMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; INJECTION SITE; LEUKOPENIA; MUSCLE WEAKNESS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SENSORY NEUROPATHY; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 0037405505     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000059584.47272.9d     Document Type: Article

References (20)

1. Dirnhofer, S., Berger, C., Hermann, M., Steiner, G., Madersbacher, S. and Berger, P.: Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate, 35: 212, 1998
2. Ben-Josef, E., Yang, S.-Y., Ji, T. H., Bidart, J.-M., Garde, S. V., Chopra, D. P. et al: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol, 161: 970, 1999
3. Bhasin, S., Berman, N. and Swerdloff, R. S.: Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl, 15: 386, 1994
4. Huhtaniemi, I., Venho, P., Jacobi, G. and Rannikko, S.: Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer. J Androl, 12: 46, 1991
5. Mahler, C., Verhelst, J., Chaban, M. and Denis, L.: Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue. Cancer, 67: 557, 1991
6. Khan, M. S. and O'Brien, A.: An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol Int, 60: 33, 1998
7. Garnick, M. B. and Campion, M.: Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol, 4: 275, 2000
8. Lamharzi, N., Schally, A. V. and Koppan, M.: Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept, 77: 185, 1998
9. McLeod, D., Zinner, N., Tomera, K., Gleason, D., Fotheringham, N., Campion, M. et al: A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology, 58: 756, 2001
10. Trachtenberg, J., Gittleman, M., Steidle, C., Barzell, W., Friedel, W., Pessis, D. et al: A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol, 167: 1670, 2002
11. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M. et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17: 3461, 1999
12. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L. et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92: 205, 2000
13. Simon, R.: Optimal two-stage designs for phase II clinical trials. Control Clin Trials, 10: 1, 1989
14. Huirne, J. A. and Lambalk, C. B.: Gonadotropin-releasing-hormone-receptor antagonists. Lancet, 358: 1793, 2001
15. Gonzalez-Barcena, D., Vadillo-Buenfil, M., Gomez-Orta, F., Fuentes Garcia, M., Cardenas-Cornejo, I., Graef-Sanchez, A. et al: Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 24: 84, 1994
16. Gonzalez-Barcena, D., Vadillo-Buenfil, M., Cortez-Morales, A., Fuentes-Garcia, M., Cardenas-Cornejo, I., Comaru-Schally, A. M. et al: Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology, 45: 275, 1995
17. Glode, L. M., Smith, J. A., Jr. and The Leuprolide Study Group: Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide. J Urol, 137:57, 1987
18. Bracci, U., Di Silverio, F., Sciarra, F., Sorcini, G., Piro, C. and Santoro, F.: Hormonal pattern in prostatic carcinoma following orchidectomy: 5-year follow-up. Br J Urol, 49: 161, 1977
19. Huhtaniemi, I. T., Dahl, K. D., Rannikko, S. and Hsueh, A. J.: Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy. J Clin Endocrinol Metab, 66: 308, 1988
20. Varenhorst, E., Wallentin, L. and Carlstrom, K.: The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol, 16: 31, 1982